Press Release

Ranbaxy Laboratories Ltd has informed BSE regarding a Press Release dated October 21, 2013, titled " (i) Ranbaxy receives CDSCO approval to market SynriamTM in India for treatment of malaria caused by Plasmodium vivax parasite (ii) Single treatment for both Plasmodium vivax and Plasmodium falciparum malaria and (iii) Permission received to conduct Phase III clinical trials for pediatric formulation”.

Source : BSE - >www.bseindia.com

Published on October 21, 2013
TOPICS

Related

This article is closed for comments.
Please Email the Editor